HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection

AIDS. 2024 Mar 15;38(4):607-610. doi: 10.1097/QAD.0000000000003792. Epub 2023 Nov 16.

Abstract

We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed during ART, suggesting (pro)viruses at initiation or during treatment may identify individuals with susceptible virus for bNAb interventional trials.

MeSH terms

  • Broadly Neutralizing Antibodies
  • HIV Infections* / drug therapy
  • HIV Seropositivity*
  • HIV-1*
  • Humans
  • Leukocytes, Mononuclear

Substances

  • Broadly Neutralizing Antibodies